Atinvicitinib, a novel, second-generation selective JAK1 inhibitor for the treatment of allergic dermatitis and atopic dermatitis in dogs

The onset of allergic dermatitis in dogs involves a complex immunological cascade which is largely mediated by the JAK-STAT signalling pathway. Several isolated enzyme and cell-based signalling pathway engagement assays were performed in vitro to evaluate the potency and selectivity of atinvicitinib, a novel second-generation JAK inhibitor. Atinvicitinib inhibited JAK1, JAK2, JAK3, and TYK2 activity in isolated human enzyme assays with IC 50 s of 0.43, 5.9, 1130 and 13.02 nM respectively, demonstrating a greater than 10-fold selectivity for JAK1 over the other JAK enzymes. When evaluated against a panel of 265 human kinases, atinvicitinib displayed a greater than 900-fold selectivity for JAK1. Additionally, when tested at a concentration of 10 µM against a panel of 112 rat, guinea pig, or human enzymes, transporters and receptors, atinvicitinib did not demonstrate stimulatory or inhibitory activity. The signalling of IL-6 (JAK1/JAK2) and EPO (JAK2) in human cell-based pathway engagement assays was inhibited by atinvicitinib with IC 50 s of 41.5 and 456 nM, respectively, consistent with the > 10-fold JAK1 selectivity displayed in isolated JAK enzyme assays. The signalling of JAK1 dependent cytokines involved in inflammation and allergy (IL-4 and IL-13) and pruritus (IL-31) in canine DH82 cells was inhibited by atinvicitinib at IC 50 s between 2.9 and 33.6 nM. These results demonstrate that atinvicitinib selectively inhibits JAK1 enzyme activity in human enzyme and cell-based assays in vitro, and that its potency against canine JAK1 in a canine cell-based system is comparable to that in human cells. While additional complementary studies are warranted, these data indicate the potential of atinvicitinib to selectively inhibit pro-inflammatory (IL-2 and IL-6), pro-allergenic (IL-4 and IL-13) and pruritogenic (IL-31) JAK1-dependent cytokines in canine allergic dermatitis.

Authors

Institutions

Publication Details

Journal
BMC Veterinary Research
Published
2026-11-16
DOI
https://doi.org/10.1186/s12917-026-06047-w
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Atinvicitinib, a novel, second-generation selective JAK1 inhibitor for the treatment of allergic dermatitis and atopic dermatitis in dogs

Jonathan Young, Timothy J. Kowalski, Rafael Fernández, Joep Verdellen et al.
1 links
BMC Veterinary Research
Dermatology and Skin Diseases
article

Atinvicitinib, a novel, second-generation selective JAK1 inhibitor for the treatment of allergic dermatitis and atopic dermatitis in dogs

Jonathan Young, Timothy J. Kowalski, Rafael Fernández, Joep Verdellen, Youri Post, Sara Dinverno, Jason Brubaker
article en

Abstract

The onset of allergic dermatitis in dogs involves a complex immunological cascade which is largely mediated by the JAK-STAT signalling pathway. Several isolated enzyme and cell-based signalling pathway engagement assays were performed in vitro to evaluate the potency and selectivity of atinvicitinib, a novel second-generation JAK inhibitor. Atinvicitinib inhibited JAK1, JAK2, JAK3, and TYK2 activity in isolated human enzyme assays with IC 50 s of 0.43, 5.9, 1130 and 13.02 nM respectively, demonstrating a greater than 10-fold selectivity for JAK1 over the other JAK enzymes. When evaluated against a panel of 265 human kinases, atinvicitinib displayed a greater than 900-fold selectivity for JAK1. Additionally, when tested at a concentration of 10 µM against a panel of 112 rat, guinea pig, or human enzymes, transporters and receptors, atinvicitinib did not demonstrate stimulatory or inhibitory activity. The signalling of IL-6 (JAK1/JAK2) and EPO (JAK2) in human cell-based pathway engagement assays was inhibited by atinvicitinib with IC 50 s of 41.5 and 456 nM, respectively, consistent with the > 10-fold JAK1 selectivity displayed in isolated JAK enzyme assays. The signalling of JAK1 dependent cytokines involved in inflammation and allergy (IL-4 and IL-13) and pruritus (IL-31) in canine DH82 cells was inhibited by atinvicitinib at IC 50 s between 2.9 and 33.6 nM. These results demonstrate that atinvicitinib selectively inhibits JAK1 enzyme activity in human enzyme and cell-based assays in vitro, and that its potency against canine JAK1 in a canine cell-based system is comparable to that in human cells. While additional complementary studies are warranted, these data indicate the potential of atinvicitinib to selectively inhibit pro-inflammatory (IL-2 and IL-6), pro-allergenic (IL-4 and IL-13) and pruritogenic (IL-31) JAK1-dependent cytokines in canine allergic dermatitis.

BMC Veterinary Research
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), ET International (United States) (US)
Good health and well-being
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon